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Diphtheria perceived as low risk 
•However, one of the largest epidemics was observed in 
1990s in WHO EU region 
•Sporadic cases of C. diphtheriae and C. ulcerans detected in 
some EU countries 
- Recent large outbreaks are ongoing in other WHO regions (India, Indonesia, 
Sudan) 
•Latvia continues to experience highest incidence in the entire 
WHO EU region 
•But waning immunity and minimal awareness causes 
diphtheria to be a threat and could return in epidemic 
proportions to Europe 
Good surveillance and laboratory detection of organisms 
is crucial for accurate diagnosis and a strong EU network 
will maintain these specialist skills 
At request of WHO EURO, 
ELWGD established in 1993 
DIPNET was DGSANCO-funded 
between 2001 – 2009 
ECDC inherited network in 2010 
and now expanded to all EU/EEA 
countries 
Laboratory activities tendered to 
HPA, London 
Continues to integrate 
microbiologists and 
epidemiologists 
European Diphtheria Surveillance 
Network – Laboratory activities 
 
‘Coordination of a European laboratory network to 
strengthen laboratory diagnostics for diphtheria 
surveillance’ 
 
• WP1: Coordination of the laboratory surveillance network of 
diphtheria 
• WP2: Organisation of EQA scheme for the reference laboratory 
diagnostics of diphtheria 
• WP3: Evaluation and assessment of serological immunity methods 
and EQA scheme of diphtheria (subcontracted to Institut Superiore di Sanita, 
Italy) 
• WP4: Provision of hands-on practical laboratory training workshops 
in diagnostic methods 
        
    
EDSN Activities to date 
•Two annual meetings 
–June 2010 and March 2011 
•Two diagnostic EQAs 
–June 2010 and May 2012 
•One serology EQA 
–January 2012 
•Two training workshops 
–July 2010 and November 2011 
Laboratory Diagnostics Workshops 
(WP4) 
• July 2010, London: 4 ‘newcomer’ participants, Belgium, 
Hungary, Malta and Luxembourg 
• November 2011, Athens: 14 participants, based on 2010 
EQA results and ‘newcomers’ 
  
 
Three day workshop, topics covered; 
– clinical, epidemiology and microbiological talks 
– primary culture, screening tests & identification methods 
– phenotypic and molecular toxigenicity testing 
– demonstration of serological assays 
– discussions on screening throat swabs and problems acquiring 
reagents 
 
Diphtheria diagnostics: Key lab 
tests 
• Gram positive rods 
• Black colonies on 
Hoyles/Tellurite media 
• Essential tests: Catalase pos, 
Cystinase pos, Pyrazinamidase 
neg 
• Four C.diphtheriae biovars: mitis, 
gravis, belfanti, intermedius 
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Laboratory Diagnosis of Diphtheria 
Workshop November 2011 – Athens, 
Greece 
 
Laboratory diagnostic EQAs (WP2): 
Preparation & despatch 
•Laboratory Questionnaire sent April 2010 to all 30 
participants 
– Level of Reference, Laboratory Diagnosis, Toxigenicity Testing, 
Serological Assays, Culture Collections, Antibiotic Sensitivity, 
Epidemiological Typing, EQA Participation 
 
•Each panel consisted of six simulated throat swabs 
– target organisms selected and checked by SDRS, HPA 
– ‘specimens’ prepared and freeze-dried by Quality Assurance Lab, 
HPA 
– panel checked for content by SDRS before shipping to participants 
 
Participants sent back results to HPA for analysis 
Fully concordant result = matched identification, biotype and 
toxigenicity 
Acceptable result = did not match biotype 
       
  
Laboratory diagnostic EQA 
Performance of centres 
2010 EQA 
•Measured by a fully correct or 
acceptable result; 
- Only five centres produced 
acceptable results for all six 
strains 
· Denmark, France, Malta, 
Norway and the UK 
•156 available reports (6 strains, from 
26 centres) 
- 21 (14%) unacceptable 
identification reports (at 
species level) 
- 16 (10%) unacceptable 
toxigenicity reports 
2012 EQA 
•Measured by a fully correct or 
acceptable result; 
- Ten centres produced 
acceptable results for all six 
strains 
· Austria, Cyprus, France, 
Iceland (ID only), Malta (ID 
only), the Netherlands, 
Norway, Slovakia, the UK 
and the USA 
·186 available reports (6 strains, from 
31 centres) 
- 18 (10%) unacceptable 
identification reports (at species 
level) 
- 20 (11%) unacceptable 
  
Participant problems 
•Centres still experience difficulties with the Elek test 
- Several countries received specialised media and reagents from HPA, 
which are becoming increasingly difficult to obtain 
- Performing test can be difficult to interpret – training workshops are key 
- False negative toxigenic results, would impact negatively on the speed of 
public health action and patient management 
 
•Isolation and identification of target organism also problematic 
- Eleven countries reported worse results for the recent EQA, mostly due to 
incorrect identification 
- Identification systems should not be solely relied upon – if identity is <95%, 
additional tests may be required 
Serology EQA 
Coordinated by ISS, Rome, Italy 
•Important for monitoring vaccine efficacy, individual & 
population immunity 
•Sixteen centres tested blind panel of 150 sera 
- Using Vero cell TNT, DELFIA, MIA or ELISA 
•Reference assay selected was the TNT from lab I (TNT 
currently gold standard) 
- Participants compared on quantitative and qualitatitve basis 
 
•Performance of labs using the TNT was generally very good 
(n=4) 
•in vitro methods such as dDA-DELFIA or MIA was also good 
(n=2) 
            
     
Conclusions 
•The quality of surveillance data is strongly supported 
through regular EQA exercises so as to ensure prompt and 
accurate microbiological diagnoses 
- These EQA results indicated that further training and EQA 
exercises are essential to maintain expertise and assess 
capabilities in the EU 
 
•Participating in training and EQAs gives confidence and 
encourages people to expand their diphtheria laboratory 
capabilities 
 
•There still remains an urgent need to continue the network 
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